Alzheimer’s disease (AD) is a neurodegenerative condition that is strongly linked with age and accounts for 60-70% of all cases of dementia. Early onset Alzheimer’s disease, which accounts for approximately 2 3% of AD cases, is a hereditary condition that is strongly associated with mutations in presenilin 1 (PSEN1), amyloid precursor protein (APP) and presenilin 2 (PSEN2) genes.
We spoke with Selina Wray, Professor of Molecular Neuroscience and Alzheimer’s Research UK Senior Research Fellow in the Department of Neurodegenerative Disease at UCL Queen Square Institute of Neurology, London.
Selina explained how developing in vitro models of Alzheimer’s Disease using iPSC’s derived from patient cells will improve translation of therapies to the clinic for the treatment of this neurodegenerative disease.
Carefully executed and quality controlled our reprogramming service ensures the resulting cell line is viable and properly characterized
We differentiate cells to disease-relevant cell types generating an unlimited source of human tissue containing complex genetic signatures
We can insert or knockout relevant disease mutations from iPSCs to create custom disease models or isogenic controls
Our custom iPSC research capabilities enables an end-to-end solution for customers, from reprogramming through to assay development and data acquisition
Fill in the form and our team of experts will get back to you with answer to your query
Could this new assay made using human stem cells revolutionize ALS research?
Axol is a leading provider of product and service solutions in the iPSC-based neuroscience, immune cell, and cardiac modeling for drug discovery and screening markets. Our custom research capabilities in gene editing, electrophysiology, reprogramming, and differentiation means we can offer customers validated ready-to-use cell lines and a suite of services bolstered by deep scientific expertise and robust functional data – all with shorter lead times
Join expert speakers at our upcoming webinar
Access our presentation now
We’re excited to be back! And, we’re especially interested to learn how you’re innovating in this space. Why do you SCIENCE with human cells? Or even, HOW do you SCIENCE with human iPSCs?
